Investor Presentation Q1 2023
108
Investor presentation
First three months of 2023
EMEA at a glance
EMEA
Million
300
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
25%
First quarter of
2023
Sales
(mDKK)
Growth²
Total GLP-13
5,048
57%
I
19%
I
I
I
200
I
150
100%
Long-acting insulin
1,899
-5%
80%
Premix insulin5
705
4%
100
I
36%1
GLP-1
Fast-acting insulin
1,723
-7%
60%
Human insulin
510
-3%
260
Insulin
Total insulin
100
195
3.24%1
40%
4,837
-5%
158
50
50
Other Diabetes care?
165
-7%
20%
Diabetes care
10,050
19%
OAD
13%1
0
2021
0
0%
Obesity care8
1,216
71%
2030
2045
Feb
2018
Feb
2023
Diabetes & Obesity
11,266
23%
Population with diabetes
Diabetes growth rate
care
-GLP-1 MS
-Insulin MS
OAD MS
Rare disease⁹
1,476
-12%
Total
12,742
18%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Feb 2023: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1
value market shares, as of Feb 2023: Novo Nordisk 61%, Eli Lilly 37% and
AstraZeneca 2%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT,
Feb 2023 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises RyzodegⓇ and
NovoMixⓇ: 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises NovoNormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®; 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Esperoct®, RefixiaⓇ,
Norditropin, Vagifem® and Activelle®View entire presentation